RxDoctor Payments Data

Anand Jain, MD

Gastroenterology · Atlanta, GANPI 1831489616

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Medtronic at 44.8% of the total.

$13,045in general payments, 2019–2025

Across 40 payments — averaging $326.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Sanofi$3K
  • Covidien LP$2K
  • AstraZeneca$2K
  • Merck$91
  • AbbVie$80
$196,780in research payments, 2019–2025

Across 16 payments — averaging $12,299 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$112K
  • Regeneron$40K
  • Medtronic$28K
  • Bristol Myers Squibb$17K

What the payments were for

  • Consulting fees$3,72229%
  • Speaking & faculty fees$7,52558%
  • Travel & lodging$9647%
  • Food & beverage$7446%
  • Education$911%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic18$5,838
Sanofi6$3,298
Covidien LP2$2,011
AstraZeneca9$1,728
Merck4$91
AbbVie1$80

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,045 in reported general payments places this provider in the 85th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$41,709
Medicare patients
186
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide24$22,154
Dexlansoprazole DrDexlansoprazole22$5,198
Sucralfate12$2,908
Rabeprazole Sodium41$1,877
Esomeprazole Magnesium21$1,315
Omeprazole61$720
Nitroglycerin34$632
Famotidine31$308
Amitriptyline Hcl20$272
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$262
Ondansetron Hcl19$226
Lidocaine Hcl ViscousLidocaine Hcl17$195
Ondansetron OdtOndansetron13$104
Metoclopramide Hcl16$97
Pantoprazole Sodium19$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$80$22,15424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →